Friday,
April 28
5:00pm–6:00pm
1600A—Bone Marrow Failure—Treatment of
Acquired Aplastic Anemia in Children
ASPHO Workshop
Chairs: Akiko Shimamura, Children’s Hospital, Boston, MA;
and Adrianna Vlachos, Schneider Children’s Hospital, New
Hyde Park, NY
This
session will focus on acquired marrow failure. The first
presentation will focus on the treatment and management of
acquired aplastic anemia in children. Studies pertaining to
the pediatric population will be highlighted. Issues guiding
the choice of therapy at diagnosis, at relapse and for
refractory disease will be discussed. The second presentation
will discuss the diagnosis and management of paroxysmal
nocturnal hemoglobinuria (PNH) in the pediatric population.
The clinical significance and management of PNH clones arising
in patients with aplastic anemia will be discussed.
-
Treatment Options and Management
of Aplastic Anemia in Children
Peter Kurre, Oregon Health & Science University, Portland, OR
-
Paroxysmal Nocturnal
Hemoglobinuria in Pediatric Patients
Russell E. Ware, St. Jude Children's Research Hospital, Memphis, TN
5:00pm–6:00pm
1610A—Thrombosis—Going with the Flow:
Anticoagulation Issues in Children with Congenital Heart
Disease
ASPHO Workshop
Chairs: Patricia Massicotte, University of Alberta
Hospital, Edmonton, AB, Canada; and Lori Luchtman-Jones,
Washington University, St. Louis, MO
Warfarin
is commonly used in children with congenital heart disease (CHD).
There are many challenges with the use of this anticoagulant
in children. Ultimate dosing depends on the individuals
genetic composition. Child-focused education on warfarin will
improve compliance, efficacy and safety. The hematologist with
expertise in anticoagulation can provide child-focused
education on anticoagulation and offer the cardiovascular team
management solutions for managing the complex issues
associated with anticoagulation in children with CHD.
-
Case Study and Discussion
Therese Giglia, Schneider Children's Hospital, New Hyde Park, NY
-
Child-Focused Education Package:
Warfarin
Mary Bauman, Stollery Children's Hospital, Edmonton, AB, Canada
-
Keep the Flow: Hematologists as
Part of the Cardiovascular Team in Children with
Congenital Heart Disease
Therese Giglia, Schneider Children's Hospital, New Hyde Park, NY
-
Panel
Discussion
7:00pm–9:00pm
1850A—Pediatric Hematology/Oncology Training Program
Directors' Dinner Meeting
ASPHO Dinner
Saturday,
April 29
7:00am–8:00am
2050A—Hemorrhagic Disorders
ASPHO Workshop
Chairs: Pedro A. de Alarcon, St. Jude Research Hospital,
Memphis, TN; and Marilyn Manco-Johnson, Mountain States
Hemophilia Treatment Center, Aurora, CO
This
workshop will present current information about hemophilia A
and B inhibitors and therapy with immune tolerance, including
a discussion of Factor VIII inhibitors and the International
ITI Study, Factor IX inhibitors and anaphylaxis syndrome.
7:00am–8:00am
2055A—Histiocytosis
ASPHO Workshop
Chairs: James Whitlock,Vanderbilt Children's Hospital,
Nashville, TN; and Alexandra Filipovich, Children’s Hospital
Medical Center, Cincinnati, OH
This
workshop will present recent developments in the biology,
diagnosis, evaluation and management of children with
Langerhans cell histiocytosis and hemophagocytic
lymphohistiocytosis, including updates from recently completed
and ongoing international clinical trials for these disorders.
The availability of new internet-based patient registries will
also be discussed.
-
Update on Hemophagocytic
Lymphohistiocytosis
Alexandra H. Filipovich, Children's Hospital Medical Center,
Cincinnati, OH
-
Update on Langerhans Cell
Histiocytosis
James A. Whitlock, Vanderbilt Children's Hospital, Nashville, TN
-
Update on Rare Histiocytosis
Registries
James A. Whitlock, Vanderbilt Children's Hospital, Nashville, TN
8:00am–11:00am
2100—Adult Stem Cells—A Primer for the
Clinician
PAS/ASPHO Mini Course
Chairs: Jakub Tolar, University of Minnesota, Minneapolis,
MN; and Mervin C. Yoder, Jr., Indiana University School of
Medicine, Indianapolis, IN
Target
Audience: Hematologists/oncologists, endocrinologists, basic
scientists and neurologists.
Adult
stem cells represent a technology that is being intensively
investigated currently, and this research may have wide
implications for human health. This mini course will focus on
recent research and potential applications in human health.
-
Introduction
Jakub Tolar, University of Minnesota, Minneapolis, MN
Mervin
C. Yoder, Indiana University School of Medicine,
Indianapolis, IN
-
Multipotent Adult Progenitor
Cell: Hype or Reality?
Catherine M. Verfaillie, University of Minnesota, Minneapolis, MN
-
Mesenchymal Stem Cell: Harnessing
the Power of Adult Stem Cells To Repair Tissues
Darwin Prockop, Tulane University Health Science Center, New Orleans,
LA
-
Hierarchy of Endothelial
Progenitors in Human Blood and Blood Vessels
David A. Ingram, Indiana University School of Medicine, Indianapolis,
IN
-
Cancer Stem Cell: Concept of
Human Leukemic Development
Craig T. Jordan, James P. Wilmot Cancer Center, University of Rochester
School of Medicine, Rochester, NY
Sponsored
jointly by the American Society of Pediatric
Hematology/Oncology and the Pediatric Academic Societies
8:15am–10:15am
2190A—Difficult Coagulation Consults
ASPHO Symposium
Chairs: Guy Young, Children’s Hospital of Orange County,
Mattel Children's Hospital at UCLA, Orange, CA; and Prasad
Mathew, University of New Mexico, Albuquerque, NM
Pediatric
hematologist/oncologists are frequently asked to consult on
patients with a variety of coagulation problems. While some of
these are fairly straightforward, there are some that create
significant diagnostic and therapeutic dilemmas. This session
will focus on three such areas. The first lecture will discuss
the pre-operative assessment for coagulation disorders in both
asymptomatic and symptomatic children. This lecture will focus
on what if any evaluation is needed and how to proceed if
screening tests are abnormal. The second talk will discuss the
difficulties in diagnosing and treating rare bleeding
disorders, including rare factor deficiencies and rare
platelet function disorders. The last presentation will focus
on the management of patients who wish to avoid blood products
(for religious beliefs, for example). This lecture will
discuss the available strategies for the avoidance of blood
products both in the surgical and non-surgical setting. After
attending this session, it is expected that the learner will
be able to: 1) describe the approach to the pre-operative
evaluation of children undergoing surgery from the standpoint
of potential bleeding complications; 2) discuss the diagnosis
and treatment of rare bleeding disorders; 3) identify
strategies for the avoidance of blood products for
patients/families wishing to avoid the use of such products.
-
Introduction
-
Pre-operative Evaluation for
Coagulation Disorders
Marilyn J. Manco-Johnson, University of Colorado Denver, The Health
Sciences Center, Aurora, CO
-
Rare Bleeding Disorders
Diane J. Nugent, Children's Hospital of Orange County, Orange, CA
-
Bloodless Medicine: Strategies To
Avoid/Minimize Transfusion of Blood Products
Aryeh Shander, Englewood Hospital and Medical Center, Englewood, NJ
-
Discussion
10:30am–11:30am
2300A—Best of SIOP (International Society
of Paediatric Oncology)
ASPHO Original Science Abstracts - Platform
Session
-
Omission of Required Radiotherapy
in Group III Rhabdomyosarcoma Patients
Mhamed Harif
-
MLL Rearranged Infant Acute
Lymphoblastic Leukemia is Characterized by Silencing of
the Tumor Suppressor Gene FHIT
R. Stam
-
Updated Therapeutic Results of
286 Burkitt’s Lymphoma in French African Pediatric
Oncology Group (FAPOG)
O. Shokek
10:30am–12:30pm
2330—Hematology/Oncology I
PAS/ASPHO Original Science Abstracts -
Platform Session
12:45pm–2:45pm
2550A—Challenges in Neonatal Care:
Coagulation Disturbances, IVH and Bleeding Control
ASPHO Industry Sponsored Symposium
Supported by a grant from Novo Nordisk
Pharmaceuticals, Inc.
12:45pm–2:45pm
2551A—Advances in the Diagnosis and
Management of Thalassemia and Sickle Cell Disease in Pediatric
Patients
ASPHO Industry Sponsored Symposium
Supported by a grant from Novartis Oncology
1:00pm–3:00pm
2620
Neonatal Hematology–Immunology
PAS Poster Symposium
3:00pm–5:00pm
2710A—Hematopoietic Cell
Transplantation—An Update
ASPHO Symposium
Chairs: Jakub Tolar and K. Scott Baker, University of
Minnesota, Minneapolis, MN
The
program will begin with a review of unrelated umbilical cord
blood transplantation, now a common practice in the treatment
of pediatric malignancies. The program will follow with a
presentation of the most recent data on reduced intensity
hematopoietic cell transplantation for treatment of malignant
and non-malignant diseases in children. The symposium will
conclude with an overview of immune implications of
mesenchymal stem cell infusion, including their use for graft
versus host disease prophylaxis and treatment. Cellular
therapy has yielded notable successes in the past decade and
holds considerable promise, and one should walk away from the
session with a realistic overview of the possibilities and
limitations of cellular therapy for childhood cancer.
After
attending this session, it is expected that the learner will
be able to:
1.
Identify efficacious cellular therapy approaches.
2. Recognize the limitations of cellular therapy for childhood
cancer.
-
Introduction
Jakub Tolar, University of Minnesota, Minneapolis, MN
-
Umbilical Cord Blood
Transplantation: Current Practice and Future Innovations
John E. Wagner, University of Minnesota Medical School, Minneapolis, MN
-
Non-myeloablative Hematopoietic
Cell Transplantation in Children
Morris Kletzel, Northwestern University Feinberg School of Medicine,
Chicago, IL
-
Immunobiology of Mesenchymal Stem
Cells
Katarina Le Blanc, Karolinska University, Stockholm, Sweden
-
Question
and Answer Session
Sunday,
April 30
7:00am–8:00am
3060A—Practice Management—Results of the
2005 ASPHO Compensation Study
ASPHO Workshop
Chair: Timothy C. Griffin, Cook Children's Medical Center,
Fort Worth, TX
In
the spring of 2005, ASPHO conducted a survey of its membership
regarding compensation. The preliminary results of this survey
will be presented, and members will have an opportunity to ask
questions and provide insights into the results in an open
forum.
7:00am–8:00am
3065A—Young Investigators
ASPHO Workshop
Chair: Kathleen M. Sakamoto, University of California Los
Angeles, Los Angeles, CA
This
workshop will focus on career options in pediatric
hematology–oncology. Pediatric hematologists–oncologists
representing basic/translational research, clinical research
and industry will discuss their experiences and the reasons
for their career choices. The workshop provides an opportunity
for fellows and junior faculty to interact with each other and
established faculty members and to discuss issues related to
career decisions, research directions and career development.
-
Clinical
Research—Building Your Career from the Ground Up
Smita Bhatia, Mattel Children's Hospital at UCLA, Los
Angeles, CA
-
Choosing a Career in
Basic/Translational Research
Kathleen M. Sakamoto, University of California Los Angeles, Los
Angeles, CA
-
Choosing a Career in Industry
Anne E. Hagey, Oncology Cytotoxics, Abbott Laboratories, Abbott Park,
IL
-
Discussion
8:00am–9:30am
3150—Hematology/Oncology II
PAS/ASPHO Original Science Abstracts -
Platform Session
9:45am–11:45am
3300A—Pure Red Cell Aplasia
ASPHO Symposium
Chair: Jeffrey M. Lipton, Schneider Children’s Hospital,
New Hyde Park, NY
The
pure red cell aplasias (PRCA) represent a form of bone marrow
restricted to the erythroid lineage. Research has led to new
insights into the molecular basis of erythroid development.
Transcriptional regulation of erythropoiesis will be discussed
in this symposium. In pediatrics, intrinsic stem/progenitor
cell defects are the most important cause of red cell failure.
One of the most common forms of pure red cell aplasia in
pediatric patients is Diamond-Blackfan Anemia. The clinical
and molecular basis of this disease will be presented.
Congenital dyserythropoietic anemias (CDA) are rare forms of
erythroid cytopenias. New information on the pathophysiology
of CDA will be presented during this symposium.
After
attending this session, it is expected that the learner will
be able to:
1.
Describe the biology of erythropoiesis.
2. Describe the clinical presentation and molecular basis of
Diamond-Blackfan Anemia.
3. Describe the clinical presentation and pathophysiology of
congenital dyserythropoietic anemia.
-
Introduction: How
"Pure" Is Pure Red Blood Cell Aplasia?
Jeffrey M. Lipton, Schneider Children's Hospital, New Hyde Park, NY
-
Biology of Erythroid Development
Mitchell Weiss, Children's Hospital of Phiadelphia, Philadelphia, PA
-
Clinical and Molecular Biology of
Diamond-Blackfan Anemia
Adrianna Vlachos, Schneider Children's Hospital, New Hyde Park, NY
-
Congenital Dyserythropoietic
Anemias 2006: Where Are We Now?
Bertil E. Glader, Stanford University School of Medicine, Stanford, CA
-
Question
and Answer Session
9:45am–11:45am
3305A—Rhabdomyosarcoma
ASPHO Symposium
Chairs: K. Scott Baker, University of Minnesota,
Minneapolis, MN; and Douglas Hawkins, Children's Hospital and
Regional Medical Center, Seattle, WA
This
session will focus on current results of recent clinical
trials in the treatment of rhabdomyosarcoma (RMS) and review
progress made over the consecutive Intergroup Rhabdomyosarcoma
Study Group Trials and current trials of the Soft Tissue
Sarcoma Committee within COG. The importance of radiation
therapy to achieve local control in the treatment of RMS, as
well as some of the controversies of radiation therapy in this
disease, will be discussed. New treatment modalities available
for radiation therapy delivery and their role in the treatment
of RMS will be reviewed. Finally, the session will end with a
state of the art update on current understanding of the
biological and molecular genetic features of RMS and their
implications in the diagnosis and treatment of children with
RMS.
After
attending this session, it is expected that the learner will
be able to:
1.
Discuss current treatment results of recent trials in the
treatment of RMS.
2. Identify the importance of radiation therapy in the
management of RMS and describe new ways that this treatment
may be delivered.
3. Describe recent advances in the biology of RMS and how
these impact therapeutic decisions.
-
Introduction
K. Scott Baker, University of Minnesota, Minneapolis, MN
-
Lessons Learned About the Local
Control Issues and Radiation Therapy in the Management of
Childhood Rhabdomyosarcoma
Sarah S. Donaldson, Stanford Cancer Center, Stanford, CA
-
Clinical Trials in
Rhabdomyosarcoma: Current Results
Douglas Hawkins, Children's Hospital and Regional Medical Center,
Seattle, WA
-
Impact of Biology and Genetics on
the Diagnosis and Treatment of Rhabdomyosarcoma
Frederic Barr, University of Pennsylvania School of Medicine,
Philadelphia, PA
-
Question
and Answer Session
1:45pm–3:45pm
3650—Hematologic Issues in the PICU
PAS/ASPHO Topic Symposium
Chairs: Roshni Kulkarni, Michigan State University, East
Lansing, MI; and Prasad Mathew, University of New Mexico,
Albuquerque, NM
Target
Audience: Pediatric hematologists/oncologists, pediatric
critical care physicians, pediatric surgeons and basic science
researchers in hematology.
Critically
ill children often suffer complications related to
hematological consequences of the primary illness or injury.
Timely realization of these by critical care physicians and
hematology consultants is key to improving outcomes in
critically ill children. During the past decade, hematology
research (particularly in coagulation and thrombophilia) has
given new information that will help clinicians care for these
children.
-
Introduction: Hematologic Issues
in the PICU
Prasad Mathew, University of New Mexico, Albuquerque, New Mexico
-
Disseminated Intravascular
Coagulation
Keith Hoots, The University of Texas Health Science Center and The
University of Texas M.D. Anderson Cancer Center, Houston,
TX
-
Massive Hemorrhage: A
Hematologists Perspective
Roshni Kulkarni, Michigan State University, East Lansing, MI
-
Thrombosis Including
Heparin-Induced Thrombocytopenia in the PICU
Guy Young, Children's Hospital of Orange County, Mattel Children's
Hospital at UCLA, Orange County, CA
-
Discussion
Sponsored
jointly by the American Society of Pediatric
Hematology/Oncology and the Pediatric Academic Societies
4:00pm–6:00pm
3800A—ASPHO Presidential Symposium and
Awards
ASPHO Presidential Lecture
Chair: F. Leonard Johnson, Oregon Health Sciences
University, Portland, OR
-
Welcome
F. Leonard Johnson, Oregon Health & Science University, Portland,
OR
-
ASPHO
Young Investigator Award Lectures
Rac GTPases Regulate the
Morphology and Deformability of the Erythrocyte
Cytoskeleton
Theodosia A. Kalfa
Phosphorylation-Mediated Control
of Transcriptional Repression by the Myeloid Translocation
Gene Protein, MTG16: Implications for Hematopoietic stem
Cell Self-Renewal and Leukemogenesis
Michael Engel
-
Frank
A. Oski Memorial Lecture:
Cell–Cell Interactions in the Bone Marrow: How Basic
Studies in Stem Cell Biology Informed New Therapeutics in
Cancer and Gene Therapy
David A. Williams, Cincinnati Children's Hospital Medical Center,
Cincinnati, OH
-
Distinguished Career Award
Archie Bleyer, M. D. Anderson Cancer Center, Houston, TX
6:00pm–6:30pm
3920A—ASPHO Business Meeting
ASPHO Business Meeting
6:30pm–7:00pm
3960A—ASPHO Distinguished Career Award
Reception
ASPHO Reception
7:00pm–9:00pm
3980A—Exploring von Willebrand Disease (VWD):
Approaches to Age- and Gender-Related Issues
ASPHO Industry Sponsored Symposium
Supported by a grant from ZLB Behring
Monday,
May 1
7:00am–8:00am
4050A—Congenital Thrombotic
Thrombocytopenic Purpura (TTP) Registry
ASPHO Workshop
Chair: David G. Motto, University of Michigan, Ann Arbor,
MI
Last
year we established that there was interest in the pediatric
hematology community to establish a registry for patients with
congenital TTP. This year we will describe the formation of
the registry and how individual physicians can access it and
contribute patient information. This registry will contain
descriptive information regarding the presentation, diagnosis,
treatment and outcome of patients with congenital TTP, along
with a database of ADAMTS13 mutations. Information will also
be provided regarding where physicians can obtain clinical and
research laboratory testing for ADAMTS13 activity and mutation
analysis.
7:00am–8:00am
4060A—Pediatric Cancer—Pharmacogenetics
and Pharmacogenomics: Do They Have Practical Applications?
ASPHO Workshop
Chairs: Brigitta U. Mueller, Baylor College of Medicine,
Houston, TX; and Craig A. Mullen, University of Rochester
Medical Center, Rochester, NY
This
session will review genetic polymorphisms related to drug
metabolism and their relationship to toxicity. Available
pediatric data will be reviewed specifically related to
current recommendations for genetic testing in relationship to
specific agents, as well as dose modifications. This program
will also contain a case review to highlight potential
clinical scenarios in relationship to pharmacogenetic testing.
-
Pharmacogenetics in Clinical
Trials
Lisa Bomgaars, Texas Children's Cancer Center, Houston, TX
-
Pharmacogenetics and Toxicity
Secondary to Cancer Therapy
Fatih Okcu, Texas Children's Cancer Center, Baylor College of Medicine,
Houston, TX
-
Case
Discussion
8:15am–10:15am
4180A—Chronic Organ Damage in Sickle Cell
Disease: Diagnosis, Prevention and Treatment
ASPHO Symposium
Chair: Russell E. Ware, St. Jude Children’s Hospital,
Memphis, TN
Chronic
organ damage is increasingly recognized as an important source
of morbidity and mortality for young persons with sickle cell
disease. This symposium will include descriptions of several
prospective multicenter clinical trials that focus on the
diagnosis, treatment and prevention of organ damage in this
common hematological disorder.
After
attending this session, it is expected that the learner will
be able to:
1.
Discuss ongoing prospective multicenter randomized clinical
trials that focus on brain damage in pediatric patients with
sickle cell anemia.
2. Describe prospective clinical trials that focus on spleen
and kidney damage in very young patients with sickle cell
anemia.
3. Describe new imaging modalities for transfusional iron
overload in the liver and heart, as well as studies using new
oral iron chelating agents for its therapeutic management.
-
Introduction and Overview
Russell E. Ware, St. Jude Children's Research Hospital, Memphis, TN
-
Brain—Silent Infarct
Transfusion (SIT) Trial
Michael R. DeBaun, Washington University School of Medicine, St. Louis,
MO
-
Brain—Stroke with Transfusions
Changing to Hydroxyurea (SWiTCH) Trial
Russell E. Ware, St. Jude Children's Research Hospital, Memphis, TN
-
Spleen and Kidney—Splenic
Function in Young Children: Lessons from BABY HUG
Zora R. Rogers, The University of Texas Southwestern Medical Center,
Dallas, TX
-
Spleen and Kidney—Renal
Function in Young Children: BABY HUG, Toddler HUG
Sherri A. Zimmerman, Duke University Medical Center, Durham, NC
-
Liver and Heart—New Imaging
Techniques for Transfusional Iron Overload
Thomas D. Coates, Children's Hospital of Los Angeles, Los Angeles, CA
-
Liver and Heart—Oral Iron
Chelators for the Management of Transfusional Iron
Overload
Alan R. Cohen, Children's Hospital of Philadelphia, Philadelphia, PA
-
Questions
and Panel Discussion
10:15am–12:15pm
4340—Hematology/Oncology
III
PAS/ASPHO Original Science Abstracts -
Platform Session
12:45pm–2:45pm
4490A—Exploring Inhibitors: Hemophilia A,
Hemophilia B
ASPHO Industry Sponsored Symposium
Supported by a grant from ZLB Behring
12:45pm–2:45pm
4492A—ASPHO Corporate Forum Satellite
Luncheon Symposia TBA
ASPHO Industry Sponsored Symposium
3:00pm–5:00pm
4625A—Cancer Etiology
ASPHO Symposium
Chairs: Doug K. Graham, University of Colorado at Denver
and Health Sciences Center, Denver, CO; and Julie A. Ross,
University of Minnesota, Minneapolis, MN
This
program will highlight both clinical and basic science
research into the causes of childhood cancer. The program will
begin with an overview of the epidemiology of childhood cancer
including incidence, trends and putative risk factors.
Obstacles to conducting well-designed studies in North America
will be discussed, and the establishment of a North American
Childhood Cancer Research Network will be introduced as a
means to help address some of these challenges. The program
will follow with a discussion of genetic susceptibility to
childhood cancer from single gene disorders with high
individual risk but low population frequency to common
population polymorphisms with low individual risk but high
population frequency. In the final presentation, the role the
family of tyrosine kinases has in the pathogenesis of
childhood cancer will be addressed. Current research on a
novel receptor kinase, Mer, will be presented to suggest a
potential role of this proto-oncogene in the development of
pediatric T cell leukemia and lymphoma.
After
this session, participants should be able to:
1.
Discuss the current state of knowledge regarding the
epidemiology of childhood cancer in the United States.
2. Describe the major activities of the Childhood Cancer
Research Network.
3. Identify the role of genetic susceptibility in the
development of childhood cancer.
4. Describe the role of tyrosine kinases in the pathogenesis
of pediatric cancer, and discuss how these oncogenes are being
targeted in the development of new drugs.
-
Introduction
Doug K. Graham, University of Colorado at Denver and Health Sciences
Center, Denver, CO
-
Causes of Childhood Cancer: Where
to Next?
Julie A. Ross, University of Minnesota, Minneapolis, MN
-
Tyrosine Kinases as Oncogenes in
Pediatric Cancer: The Role of the Mer Receptor Tyrosine
Kinase in Lymphoblastic Leukemia and Lymphoma
Doug K. Graham, University of Colorado at Denver and Health Sciences
Center, Denver, CO
-
Genetic Susceptibility to
Cancer—The Weak and the Strong
Stella M. Davies, Cincinnati Children’s Hospital Medical Center,
Cincinnati, OH
-
Question and Answer Session
Additional
PAS Programming of Interest
Saturday, April 29
12:00pm–3:00pm
2505
Embryonic Stem Cells: A Primer for Clinicians
PAS
Mini Course
2:15pm–5:15pm
2705
Vitamin D: More Than Just Calcium and Bone
PAS/LWPES
Mini Course
3:15pm–5:15pm
2735
Update on Therapeutic Monoclonal Antibodies
PAS
Topic Symposium
Sunday,
April 30
4:15pm–5:45pm
3810
RNA Interference, Technological Development of siRNAs
and Potential Treatments for Childhood Diseases
PAS
State of the Art Plenary
Monday,
May 1
10:15am–12:15pm
4300
SPR Presidential Plenary and Awards
12:00pm–1:00pm
4410A
23rd Annual Audrey K. Brown Kernicterus Symposium
Club
|
